EP Patent

EP2041576B1 — Differential cytokine expression in human cancer

Assigned to Apogenix AG · Expires 2011-08-10 · 15y expired

What this patent protects

The invention concerns a method for diagnosing a cancer type, whereby the expression of anti-apoptotic cytokines is determined in the tumour cells. The differential diagnosis of the present invention is used to classify tumour disorders and to recommend the required treatment and…

USPTO Abstract

The invention concerns a method for diagnosing a cancer type, whereby the expression of anti-apoptotic cytokines is determined in the tumour cells. The differential diagnosis of the present invention is used to classify tumour disorders and to recommend the required treatment and to monitor the progress and response to the treatment.

Drugs covered by this patent

Patent Metadata

Patent number
EP2041576B1
Jurisdiction
EP
Classification
—
Expires
2011-08-10
Drug substance claim
No
Drug product claim
No
Assignee
Apogenix AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.